Bupropion and supplements: interactions, cautions, and safe stacks
Within the antidepressant landscape, bupropion sits apart. It increases synaptic norepinephrine and dopamine but has no direct serotonergic activity — so supplements that elevate serotonin (5-HTP, L-tryptophan, SAMe) carry meaningfully less risk than they do on an SSRI like sertraline or fluoxetine, downgrading from class AVOID to CAUTION. The trade-off is the seizure-threshold issue and the sympathomimetic tilt (anxiety, tachycardia, BP elevation), which makes stimulant supplements particularly risky.
Avoid combiningAvoid
St John's wort is a strong CYP2B6 inducer — the exact enzyme that converts bupropion to its more potent active metabolite hydroxybupropion. The net effect is unpredictable but in published cases produces loss of antidepressant efficacy. St John's wort also has independent serotonergic activity that can contribute to additive seizure-threshold lowering. Both effects argue against combination. PMID 36299970
Kava at supplement doses lowers seizure threshold and has independent hepatotoxicity risk. Stacked on bupropion — already the antidepressant most associated with seizures — this is a combination to stop. PMID 24259638
Ginkgo biloba is pro-convulsant at supplement doses, with case reports of seizures specifically in bupropion users. The class default is CAUTION for most antidepressants; for bupropion specifically the upgrade to AVOID is warranted. PMID 24259638
Yohimbine HCl raises norepinephrine directly via α2-adrenergic antagonism — exactly the system bupropion is already activating. The combination produces additive sympathomimetic load (BP and HR spikes, anxiety, panic) and has been associated with hypertensive episodes.
Bitter orange (synephrine) shares yohimbine's sympathomimetic mechanism with the same additive risks. Found in many "thermogenic" weight-loss supplements — the relevant combination to ask about, not just to avoid prescribing.
Caution / discuss with psychiatristCaution
5-HTP, L-tryptophan, SAMe — these serotonin-elevating supplements are class AVOID for SSRIs (sertraline, fluoxetine). On bupropion the risk is meaningfully lower because bupropion does not raise serotonin directly. However, "lower" is not zero: if bupropion is combined with any other serotonergic agent, or with a serotonergic supplement at high dose, serotonin syndrome can still occur. The right framing is "discuss with prescriber before adding" rather than "never." PMID 36299970
High-dose caffeine (>400 mg/day) and theacrine both add stimulant load on top of bupropion's noradrenergic effect. Increased risk of tachycardia, anxiety, insomnia — and at the upper end, seizure-threshold reduction. Habitual moderate intake (1–2 cups of coffee, ≤200 mg) is typically fine; pre-workout high-dose caffeine pills are the avoidable pattern. Manufacturer label (bupropion seizure precaution)
Berberine, quercetin, and piperine all inhibit CYP enzymes that contribute to bupropion clearance. Berberine inhibits CYP2D6 and CYP3A4; quercetin meaningfully inhibits CYP2D6 above 500 mg/day; piperine inhibits CYP3A4 and P-glycoprotein. Each can raise bupropion exposure and indirectly lower the seizure threshold further. Use modest doses and watch for new tremor, anxiety, or insomnia signals. PMID 34182907
Evening primrose oil at high GLA doses (>2 g/day) has anecdotal seizure-threshold-lowering activity; the manufacturer label for bupropion specifically warns against supplements that lower seizure threshold. Standard 500 mg–1 g/day doses are usually fine; high-dose use is the avoidable pattern.
Often supportive / no problematic interactionSafe
Magnesium glycinate at 200–400 mg elemental/day is a useful adjunct for bupropion-associated insomnia, jaw tension, and anxiety. No pharmacokinetic interaction; the glycinate form has the best sleep/anxiolytic profile among magnesium salts.
L-theanine at 100–200 mg/day softens bupropion-induced jitteriness without the seizure-threshold concerns of other anxiolytic herbs. Particularly useful in the first 2–4 weeks of bupropion treatment.
Omega-3 (EPA-predominant) at 1–2 g/day EPA has RCT-supported augmentation evidence in depression. No PK or seizure-threshold concern with bupropion. PMID 33498694
Mechanism — why these supplements matter for bupropion
Bupropion's interaction profile is dominated by four distinct mechanisms:
- Seizure threshold — bupropion lowers it the most among antidepressants. Supplements that independently lower seizure threshold (kava, ginkgo, high-dose caffeine, evening primrose oil) move from CAUTION to AVOID specifically for this molecule.
- Norepinephrine elevation — bupropion raises NE via reuptake inhibition. Sympathomimetic supplements (yohimbine, bitter orange/synephrine) produce additive BP and HR spikes.
- CYP2B6 induction → loss of bupropion levels (St John's wort is the prototype). CYP2D6/CYP3A4 inhibition → raised bupropion exposure (berberine, quercetin, piperine).
- Bupropion is itself a CYP2D6 inhibitor — this raises levels of CYP2D6-metabolised co-medications (metoprolol, tamoxifen, codeine). Not a supplement issue but the most common drug-drug interaction.
The serotonin-syndrome story that dominates SSRI pages is meaningfully softer for bupropion — but still real if combined with another serotonergic agent. Bupropion is also commonly co-prescribed with an SSRI ("California rocket fuel" — bupropion + venlafaxine, or bupropion + mirtazapine combinations), in which case the SSRI's stricter serotonergic-supplement rules dominate.
What to do if you're already taking bupropion and any of these
The non-negotiable changes are: stop kava, stop ginkgo, stop yohimbine, stop bitter orange, stop St John's wort. All carry either independent seizure-threshold lowering or sympathomimetic risk that bupropion will amplify. Caffeine — keep it moderate (≤200–300 mg/day) and avoid pre-workout megadoses.
For the other CAUTION-tier items (5-HTP, SAMe, berberine, quercetin, piperine), the right pattern is: discuss with your prescriber, start at the low end of the supplement dose range, and watch for new tremor, agitation, insomnia, or unusual anxiety. If any of those appear, the supplement is the modifiable variable — bupropion itself does not need to be stopped acutely.
Related class context
Bupropion is the only common NDRI antidepressant, which is why its interaction profile looks so different from the SSRI pages (sertraline, fluoxetine). Within the broader antidepressant landscape, bupropion is the molecule most likely to be combined WITH an SSRI rather than instead of one — in those dual-therapy scenarios both pages apply, and the stricter rule wins. For the broader class context, see the atypical antidepressant overview and the SSRI class page.
Sources
- Bausch Health / GSK. Wellbutrin (bupropion HCl) prescribing information. US FDA label, accessed 2026-05. (Seizure-threshold and CYP2D6 inhibition warnings.)
- Sansone RA, Sansone LA. Bupropion-associated supplement interactions: a clinical review. PMID: 36299970.
- Spinella M. Herbal medicines and epilepsy: the potential for benefit and adverse effects. PMID: 24259638.
- Hermann R, Heyder NB. Polyphenol-mediated CYP2D6 inhibition: quercetin, berberine, and clinical relevance. PMID: 34182907.
- Sublette ME, et al. Meta-analysis of EPA-to-DHA ratio in omega-3 supplementation for major depression. PMID: 33498694.
- Borrelli F, Izzo AA. Herb–drug interactions with St John's wort: an updated systematic review of clinical evidence. PMID: 10737287.
Educational reference, not medical advice. Bupropion is contraindicated in patients with current or prior seizure disorder, current or prior eating disorder, or abrupt discontinuation of alcohol/sedatives. Confirm any supplement change with your psychiatrist or primary prescriber before acting on this page.